SCHEMBL4075169

SCHEMBL4075169

N#CC(c1ccccc1)c1ccc(NC(=O)CCCC(=O)Nc2ccc(C(C#N)c3ccccc3)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.67
AKR1C3 P42330 1/20 0.67
AKR1C1 Q04828 1/20 0.67
HDAC4 P56524 8/20 0.51
HDAC1 Q13547 8/20 0.51
HDAC7 Q8WUI4 8/20 0.51
HDAC11 Q96DB2 8/20 0.51
HDAC8 Q9BY41 8/20 0.51
HDAC6 Q9UBN7 8/20 0.51
HDAC9 Q9UKV0 8/20 0.51
HDAC5 Q9UQL6 8/20 0.51
HDAC3 O15379 7/20 0.51
HDAC2 Q92769 7/20 0.51
HDAC10 Q969S8 7/20 0.51
POLB P06746 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
CYP3A4 P08684 2/20 0.50
GAA P10253 1/20 0.50
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4075171 0.96 ALDH1A1 (0.62) ALDH1A1AKR1C3AKR1C1HDAC4HDAC1
SCHEMBL6296181 0.77 HDAC4 (0.75) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL8650396 0.76 HDAC4 (0.65) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL11162134 0.76 CYP3A4 (0.71) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL18061419 0.75 ALDH1A1 (0.74) ALDH1A1AKR1C3AKR1C1POLBMEN1
SCHEMBL14934810 0.75 HDAC4 (0.64) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL11763815 0.74 ALDH1A1 (0.63) ALDH1A1AKR1C3AKR1C1POLBMEN1
SCHEMBL11765892 0.74 ALDH1A1 (0.63) ALDH1A1AKR1C3AKR1C1POLBMEN1
SCHEMBL14934830 0.74 HDAC4 (0.67) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL14934660 0.74 HDAC4 (0.67) HDAC4HDAC1HDAC7HDAC11HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed
EP-1745010-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2007-01-24 EP disclosed
WO-2005110974-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD ALDH1A1 158/4885AKR1C3 517/4885AKR1C1 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.